Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-345-5p mimic
- Development stage
- Preclinical
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous, Intraperitoneal
01
Overview
miR-345-5p mimic is a synthetic RNA oligonucleotide designed to replicate the biological activity of the endogenous microRNA miR-345-5p. In preclinical research, it acts as a tumor suppressor in various cancers, including pancreatic cancer, lung adenocarcinoma, and papillary thyroid carcinoma, by downregulating specific oncogenic targets. In pancreatic cancer, it has been shown to attenuate metastasis by targeting the KLK7/E-Cad/β-Catenin/Rap1 axis. In other contexts, it targets RhoA, SETD7, and SOCS1. It is primarily used as a research tool to study gene regulation and potential therapeutic pathways in oncology and neuropsychiatric disorders like depression.
- Other names
- hsa-miR-345-5p mimichsa-miR345-5p mimichsa-miR 345-5p mimicmicroRNA-345-5p mimicmicroRNA345-5p mimicmicroRNA 345-5p mimic
02
Targets
KLK7Ras homolog family member A (mRNA)SETD7 (SET domain containing lysine methyltransferase 7)SOCS1 (Suppressor of cytokine signaling 1)RHOA (Ras homolog gene family member A)
Beyond the preview
Go deeper on miR-345-5p mimic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-345-5p mimic.